Here are the S-3 shelf registrations from Relmada Therapeutics, Inc. (RLMD) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow RLMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RLMD filings page.
Relmada Therapeutics, Inc. filed an automatic shelf registration on Form S-3 that registers for resale 29,474,569 shares of common stock and shares issuable upon exercise of pre-funded warrants to purchase up to 4,210,527 shares, related to a $160.0 million private placement closed March 9, 2026; the registration was declared effective on April 9, 2026.
The base prospectus also registers a variety of other equity and equity-linked securities (common stock, preferred stock, warrants, subscription rights, depositary shares, purchase contracts and units) for future offerings from time to time. Net proceeds from the private placement are stated to be used for working capital and general corporate purposes, including advancement of R&D for NDV-01 and Sepranolone development programs.
Relmada Therapeutics, Inc. filed a preliminary prospectus on a registration statement to register the resale of 33,685,096 shares of common stock, consisting of 29,474,569 issued shares and 4,210,527 shares underlying pre-funded warrants issued in a private placement. The shares are being registered for resale by the selling stockholders and the company will not receive proceeds from those resales. The private placement closed March 11, 2026 for aggregate gross proceeds of approximately $160.0 million (shares at $4.75 and pre-funded warrants at $4.749). Shares outstanding were 104,888,233 as of March 20, 2026; the last reported sale price was $6.99 per share on April 2, 2026.